HBOT Conversations:
Dr. Hemal Mehta & Fasting (Part 2)
Dr. Hemal Mehta, MD is a Medical Director and an Independent Medical Examiner who focuses on pain management through a Regenerative medicine approach. Dr. Mehta is Board Certified in Physical Medicine and Pain Management. He received his Doctor of Medicine Degree from Ross University School of Medicine and completed his residency at East Carolina. He is the Medical Director of Vibrant Health of North Carolina, Tennessee Integrative Pain Institute, and TN Integrative Healthcare: Musculoskeletal and Regenerative Center; additionally, Dr. Mehta is the attending physician at Nashville Regenerative Orthopedics. Dr. Mehta is the 2013 recipient of the Inaugural Patient Appreciation Award at Nashville Academy of Medicine, and the 2004 Research Resident of the Year for East Carolina University. Dr. Mehta has extensive experience with stem cell proliferation, and angiogenesis. He has incorporated Ozone Injection Therapy, PRP (Platelet-Rich Plasma) Injections, Hyperbaric Oxygen Therapy and Regenerative Matrix and Regenerative Medicine Procedures – to name a few – into his integrative wellness & longevity medical practices.
Watch the Podcast
di Girolamo & Dr. Mehta examine the use of Vitamin C IV therapy for cancer, and how the combination of Vitamin C IV therapy, fasting and oxygen therapy – especially in the form of Hyperbaric Oxygen Therapy – has been known to put patients in remission and completely eliminate some very serious cancers. Dr. Mehta describes Hyperbaric Oxygen as a “game changer” when adding it into a cancer treatment protocol. He explains that as doctors they are trained to look at chemotherapy first to treat cancer, but there are many holistic ways to help a cancer patient shrink the tumors, stop the spread and live a longer life. He agrees that HBOT would be a great option to help cancer patients on their healing journey.
Diet is another holistic way to treat cancer. A water fast that puts the body in a ketogenic state, or a ketogenic organic diet are all ranked high as ideal ways to use alternative, natural methods for cancer and pain relief.
Dr. Mehta tells a personal story of his past that involved his father’s diagnosis of papillary thyroid cancer, and how it was the holistic and natural methods Dr. Mehta recommended that gave him extended life. Vitamin C Therapy, consuming organic wheatgrass daily, and daily deep breathing techniques to increase oxygen levels all contributed to him living 3 years longer than his prognosis. After massive shrinkage of the tumors during those 3 years; his father was convinced by an Ocologist to undergo chemotherapy in hopes that it would completely eradicate the cancer from his body. The chemotherapy caused cardio toxicity and unfortunately ultimately lead to Dr. Mehta’s father passing away.
di Girolamo suggests that viewers watch Research Rundown Episode 16: The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer. This is a popular Research Rundown where our host, Ed di Girolamo, analyzes a study led by researcher, Dominic D’Agostino. The benefit of combining ketogenic diet with Hyperbaric Oxygen Therapy (HBOT) for metastatic cancer treatment is some very exciting research in the world of HBOT, cancer research, and fasting! This particular research and Dominic’s involvement to help prove that cancer can be eliminated (and maybe even cured) by combining a heavy ketogenic diet and Hyperbaric Oxygen Therapy is further discussed in this HBOT News Conversations episode with Dr. Mehta.
*Pease consult your doctor to see if fasting is right for you.
Guest
Dr. Hemal Mehta
Subscribe Now, It’s Free!
Recent HBOT News
Clinical Trial – 1% Chloroprocaine(PF) vs. Bupivacaine Spinals
The use of 1% Chloroprocaine (PF) spinal anesthesia will reduce the recovery times and
discharge time of patients undergoing hemorrhoidectomies as compared to 0.75% bupivacaine
spinal. The primary objective is to compare the recovery times (return of motor and sensory
function) and discharge time (voiding time) between 2-Chloroprocaine and 0.75% bupivacaine
spinal anesthesia for hemorrhoidectomies. This is a randomized, prospective study assigning
patients to either 2-Chloroprocaine (PF) or 0.75% bupivacaine spinal anesthesia group.
Clinical Trial – RCT of Epinephrine (None, 100mcg, and 200mcg) in a Hyperbaric Bupivacaine, Fentanyl and Morphine Spinal in C-sections.
This is a prospective, randomized, double blind study of 75 patients (n=25 for each group) in
which epinephrine (100mcg or 200mcg) or normal saline vehicle is added to intrathecal
hyperbaric bupivacaine (0.75% bupivacaine hydrochloride in 8.25% dextrose), fentanyl, and
morphine to prolong the duration of the spinal anesthetic in scheduled cesarean deliveries.
The primary outcome of duration will be the time to T10 level sensory regression as well as
motor level regression that will be graded via the modified Bromage scale.
Repeat cesarean sections, in particular, are associated with increased operative time and
thus often performed with a spinal-epidural (CSE) technique. The epidural component is,
however, untested and may not provide adequate anesthesia, thus the higher risk of conversion
to a general anesthesia. Epinephrine is routinely used to prolong spinal anesthesia. If
effective for the duration of a repeat cesarean section it would obviate the additional time
and risks of performing the epidural and still avoid sufficient duration to avoid conversion
to a general anesthetic.
Current treatment of central retinal artery occlusion: a national survey.
Central retinal artery occlusion (CRAO) is an ophthalmological emergency, the retinal analog of a stroke. To date there is no consensus or national guidelines on how this disorder should be managed. As academic neurologists and ophthalmologists treat CRAO frequently, we set out to understand how these clinicians approach patients with CRAO with a national survey. We identified university-associated teaching hospitals offering vascular neurology, neuro-ophthalmology and/or retina fellowships in the US and asked the directors of the programs to respond to questions in an open response format to profile the acute management of CRAO at their institution.